Molndal, Sweden

Mikael Ulf Johan Dahlstrom



Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 518(Granted Patents)


Location History:

  • Molndal, SE (2006 - 2007)
  • Mölndäl, SE (2007)
  • Mölndal, SE (2008 - 2011)

Company Filing History:


Years Active: 2006-2011

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mikael Ulf Johan Dahlstrom

Introduction

Mikael Ulf Johan Dahlstrom is a notable inventor based in Molndal, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating hyperlipidaemia. With a total of 8 patents to his name, Dahlstrom's work has had a considerable impact on medical science.

Latest Patents

Dahlstrom's latest patents include innovative compounds such as benzothiazepine derivatives. These compounds are described as pharmaceutically acceptable salts, solvates, and prodrugs, which serve as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Additionally, he has developed diphenylazetidinone derivatives that act as cholesterol absorption inhibitors, also aimed at treating disorders of lipid metabolism. The processes for their manufacture and the pharmaceutical compositions containing these compounds are also detailed in his patents.

Career Highlights

Throughout his career, Dahlstrom has worked with prominent companies in the pharmaceutical industry, including AstraZeneca AB and Albireo AB. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development in the field.

Collaborations

Dahlstrom has collaborated with several professionals in his field, including Ingemar Starke and Suzanne Alenfalk. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Mikael Ulf Johan Dahlstrom's contributions to pharmaceutical innovations are noteworthy. His patents reflect a commitment to advancing medical treatments for hyperlipidaemia and lipid metabolism disorders. His work continues to influence the pharmaceutical landscape significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…